Pharsight

Amrix patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8877245 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants
Nov, 2023

(5 months ago)

US9399025 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants
Nov, 2023

(5 months ago)

US7820203 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants
Nov, 2023

(5 months ago)

US9375410 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants
Nov, 2023

(5 months ago)

US7829121 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants
Nov, 2023

(5 months ago)

US7544372 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants
Nov, 2023

(5 months ago)

US7790199 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants
Nov, 2023

(5 months ago)

US7387793 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants
Feb, 2025

(10 months from now)

Amrix is owned by Teva Pharms Intl.

Amrix contains Cyclobenzaprine Hydrochloride.

Amrix has a total of 8 drug patents out of which 7 drug patents have expired.

Expired drug patents of Amrix are:

  • US8877245
  • US9399025
  • US7820203
  • US9375410
  • US7829121
  • US7544372
  • US7790199

Amrix was authorised for market use on 01 February, 2007.

Amrix is available in capsule, extended release;oral dosage forms.

Amrix can be used as relief of muscle spasm.

The generics of Amrix are possible to be released after 26 February, 2025.

Drugs and Companies using CYCLOBENZAPRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 01 February, 2007

Treatment: Relief of muscle spasm

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of AMRIX before it's drug patent expiration?
More Information on Dosage

AMRIX family patents

Family Patents